Online Hemodiafiltration Inhibits Inflammation-Related Endothelial Dysfunction and Vascular Calcification of Uremic Patients Modulating miR-223 Expression in Plasma Extracellular Vesicles

J Immunol. 2019 Apr 15;202(8):2372-2383. doi: 10.4049/jimmunol.1800747. Epub 2019 Mar 4.

Abstract

Decreased inflammation and cardiovascular mortality are evident in patients with end-stage chronic kidney disease treated by online hemodiafiltration. Extracellular vesicles (EV) are mediators of cell-to-cell communication and contain different RNA types. This study investigated whether mixed online hemodiafiltration (mOL-HDF) beneficial effects associate with changes in the RNA content of plasma EV in chronic kidney disease patients. Thirty bicarbonate hemodialysis (BHD) patients were randomized 1:1 to continue BHD or switch to mOL-HDF. Concentration, size, and microRNA content of plasma EV were evaluated for 9 mo; we then studied EV effects on inflammation, angiogenesis, and apoptosis of endothelial cells (HUVEC) and on osteoblast mineralization of vascular smooth muscle cells (VSMC). mOL-HDF treatment reduced different inflammatory markers, including circulating CRP, IL-6, and NGAL. All hemodialysis patients showed higher plasma levels of endothelial-derived EV than healthy subjects, with no significant differences between BHD and mOL-HDF. However, BHD-derived EV had an increased expression of the proatherogenic miR-223 with respect to healthy subjects or mOL-HDF. Compared with EV from healthy subjects, those from hemodialysis patients reduced angiogenesis and increased HUVEC apoptosis and VSMC calcification; however, all these detrimental effects were reduced with mOL-HDF with respect to BHD. Cell transfection with miR-223 mimic or antagomiR proved the role of this microRNA in EV-induced HUVEC and VSMC dysfunction. The switch from BHD to mOL-HDF significantly reduced systemic inflammation and miR-223 expression in plasma EV, thus improving HUVEC angiogenesis and reducing VSMC calcification.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Endothelium, Vascular / immunology*
  • Endothelium, Vascular / metabolism
  • Endothelium, Vascular / pathology
  • Extracellular Vesicles* / immunology
  • Extracellular Vesicles* / metabolism
  • Female
  • Gene Expression Regulation / immunology*
  • Hemodiafiltration*
  • Human Umbilical Vein Endothelial Cells
  • Humans
  • Inflammation / blood
  • Inflammation / immunology
  • Inflammation / pathology
  • Inflammation / therapy
  • Male
  • MicroRNAs* / blood
  • MicroRNAs* / immunology
  • Middle Aged
  • Renal Insufficiency, Chronic* / blood
  • Renal Insufficiency, Chronic* / immunology
  • Renal Insufficiency, Chronic* / pathology
  • Renal Insufficiency, Chronic* / therapy
  • Uremia* / blood
  • Uremia* / immunology
  • Uremia* / pathology
  • Uremia* / therapy
  • Vascular Calcification* / blood
  • Vascular Calcification* / immunology
  • Vascular Calcification* / pathology
  • Vascular Calcification* / therapy

Substances

  • MIRN223 microRNA, human
  • MicroRNAs